Russia's first HPV vaccine 'Tsigardeks' enters civilian circulation, 30k doses to reach clinics by late September

Russia's domestically produced HPV vaccine 'Tsigardeks' (Nanolek) has been released into civilian circulation, with an initial 30,000 doses set to reach medical facilities by end of September and 600,000 doses planned by year-end. This marks a significant step in Russia's vaccine independence, though the rollout is small relative to population needs. The development is notable for public health but has limited immediate market impact.